Affiliation: Mayo Clinic
- To feed or not to feed: is that the right question?Timothy Moynihan
Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
J Clin Oncol 23:6256-9. 2005
- Missed opportunities: commentary on "The sentinel"Timothy J Moynihan
Department of Medical Oncology, Mayo Clinic, 200 First St Southwest, Rochester, MN 55905, USA
J Clin Oncol 26:1762-3. 2008
- Ependymal tumorsTimothy J Moynihan
Department of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Curr Treat Options Oncol 4:517-23. 2003..A minority of patients may respond to one of several chemotherapy regimens at the time of recurrence, but the impact of this therapy is limited. Newer treatment strategies are needed...
- Use of opioids in the treatment of severe pain in terminally ill patients--dying should not be painfulTimothy J Moynihan
Division of Medical Oncology, Mayo Clinic, Rochester, Minn 55905, USA
Mayo Clin Proc 78:1397-401. 2003..In addition to drugs administered continually, short-acting medications must be available for "breakthrough" pain. This article reviews the principles of pain management in terminally ill patients, using a case-based demonstration...
- Preparing ourselves, our trainees, and our patients: a commentary on truthtellingTimothy J Moynihan
Mayo Clinic, 200 First St, Rochester, MN 55905, USA
J Clin Oncol 25:456-7. 2007
- Palliative and end of life careRobert Stroebel
Division of Primary Care Internal Medicine, Mayo Clinic, Rochester, USA
Stud Health Technol Inform 153:71-86. 2010..An improved organizational schema could foster sustained delivery of high value delivery operations. The healthcare ecosystem needs to evolve to provide appropriate incentives and support for an appropriately designed care system...
- Applying quality-of-life data formally and systematically into clinical practiceMarlene H Frost
Women s Cancer Program, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 82:1214-28. 2007..However, the work done to date requires continued development. Continued research is needed that provides information about benefits and addresses limitations of current approaches...
- Oncologic emergencies: diagnosis and treatmentThorvardur R Halfdanarson
Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
Mayo Clin Proc 81:835-48. 2006..Prompt interventions can be lifesaving and may spare patients considerable morbidity and pain. In this review, we discuss the diagnosis of and initial therapy for common emergencies in hematology and oncology...
- Retrospective review of adjuvant chemotherapy for esthesioneuroblastomaAlyx B Porter
Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
J Neurooncol 90:201-4. 2008..Prior reviews have found efficacy of chemotherapy for high grade tumors in the advanced setting. However, little information is available regarding chemotherapy in the adjuvant setting...
- Cancer-related fatigue: an updateAmit Sood
Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Curr Oncol Rep 7:277-82. 2005..Psychostimulants seem promising based on early studies. Several complementary medicine treatments that showed efficacy in preliminary studies merit further testing...
- Characterizing care of hospice patients in the hospital settingMolly L Olsen
Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
J Palliat Med 14:185-9. 2011..One measure of quality hospice care is minimization of hospitalization. Few studies have explored reasons for hospitalization and characteristics of care received by hospice patients in the hospital...
- As-needed morphine: yes, but at what dose and at what interval?Matthew Ryan
Department of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
J Clin Oncol 23:3849-52. 2005
- Mastering the art of oncologyCharles L Loprinzi
Mayo Clinic, USA
Minn Med 88:34-5, 54. 2005
- Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignanciesShaji K Kumar
Divisions of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
Invest New Drugs 31:1201-6. 2013..Sorafenib (a VEGFR and multi-targeted kinase inhibitor) and Bortezomib (a proteasome inhibitor) have clinical antineoplastic activities as single agents, and combine synergistically in preclinical models...
- Oncologic emergenciesDeepti Behl
Hematology and Oncology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Crit Care Clin 26:181-205. 2010..Prompt recognition and treatment of these conditions can lead to markedly improved quality and quantity of life...
- Efficacy of complementary and alternative medicine therapies in relieving cancer pain: a systematic reviewAditya Bardia
Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA
J Clin Oncol 24:5457-64. 2006..This is a systematic review of randomized controlled trials (RCTs) evaluating CAM therapies for cancer-related pain...
- Malignant primary cardiac tumors: review of a single institution experienceLijo Simpson
Division of Medical Oncology, Mayo Clinic Cancer Center, Mayo Clinic, Rochester, MN 55905, USA
Cancer 112:2440-6. 2008..Primary cardiac sarcomas are uncommon. The authors undertook to review the Mayo Clinic's experience with primary cardiac sarcomas consisting of 34 patients seen over a 32-year period...
- "But doctor, what have I got to lose...?"Paul R Harnett
Department of Medical Oncology and Palliative Care, Westmead Hospital, Westmead, New South Wales, Australia
J Clin Oncol 21:27s-29s. 2003
- Assessing meaningful change in quality of life over time: a users' guide for cliniciansMirjam A G Sprangers
Department of Medical Psychology, Academic Medical Center, University of Amsterdam, The Netherlands
Mayo Clin Proc 77:561-71. 2002....